A Faster-acting and More Potent Form of Tissue Plasminogen Activator

Overview

Journal Proc Natl Acad Sci U S A

Specialty Science

Date 1994 Apr 26

PMID 8170967

Citations 83

Authors

B A Keyt

N F Paoni

C J Refino

L Berleau

H Nguyen

A Chow

J Lai

L Pena

C Pater

J Ogez

Affiliations

Soon will be listed here.

Abstract

Current treatment with tissue plasminogen activator (tPA) requires an intravenous infusion (1.5-3 h) because the clearance of tPA from the circulation is rapid (t 1/2 approximately 6 min). We have developed a tPA variant, T103N,N117Q, KHRR(296-299)AAAA (TNK-tPA) that has substantially slower in vivo clearance (1.9 vs. 16.1 ml per min per kg for tPA in rabbits) and near-normal fibrin binding and plasma clot lysis activity (87% and 82% compared with wild-type tPA). TNK-tPA exhibits 80-fold higher resistance to plasminogen activator inhibitor 1 than tPA and 14-fold enhanced relative fibrin specificity. In vitro, TNK-tPA is 10-fold more effective at conserving fibrinogen in plasma compared to tPA. Arterial venous shunt models of fibrinolysis in rabbits indicate that TNK-tPA (by bolus) induces 50% lysis in one-third the time required by tPA (by infusion). TNK-tPA is 8- and 13-fold more potent in rabbits than tPA toward whole blood clots and platelet-enriched clots, respectively. TNK-tPA conserves fibrinogen and, because of its slower clearance and normal clot lysis activity, is effective as a thrombolytic agent when given as a bolus at a relatively low dose.

Citing Articles

Intravenous Thrombolysis with Urokinase for Acute Ischemic Stroke.

Qiao Y, Wang J, Nguyen T, Liu L, Ji X, Zhao W Brain Sci. 2024; 14(10).

PMID: 39452001 PMC: 11505899. DOI: 10.3390/brainsci14100989.

Biological function of sialic acid and sialylation in human health and disease.

Zhu W, Zhou Y, Guo L, Feng S Cell Death Discov. 2024; 10(1):415.

PMID: 39349440 PMC: 11442784. DOI: 10.1038/s41420-024-02180-3.

Spinal subdural hematoma as a complication of tenecteplase treatment for acute ischemic stroke: A case report.

Zhao S, Tang L, Lu Y, Li Y Heliyon. 2024; 10(18):e37660.

PMID: 39309924 PMC: 11416295. DOI: 10.1016/j.heliyon.2024.e37660.

Safety and Efficacy of Injection Tenecteplase in 4.5 to 24 Hours Imaging Eligible Window Patients with Acute Ischemic Stroke (EAST-AIS) - Study Protocol.

Pandit A, Jatwani A, Tangri P, Srivastava M, Bhatia R, Kale S Ann Indian Acad Neurol. 2024; 27(4):408-412.

PMID: 39196809 PMC: 11418772. DOI: 10.4103/aian.aian_23_24.

Glycosylation: mechanisms, biological functions and clinical implications.

He M, Zhou X, Wang X Signal Transduct Target Ther. 2024; 9(1):194.

PMID: 39098853 PMC: 11298558. DOI: 10.1038/s41392-024-01886-1.

References

Neuhaus K, Feuerer W, Niederer W, Vogt A, Tebbe U . Improved thrombolysis with a modified dose regimen of recombinant tissue-type plasminogen activator. J Am Coll Cardiol. 1989; 14(6):1566-9. DOI: 10.1016/0735-1097(89)90399-9. View

Madison E, Goldsmith E, Gerard R, Gething M, Sambrook J . Serpin-resistant mutants of human tissue-type plasminogen activator. Nature. 1989; 339(6227):721-4. DOI: 10.1038/339721a0. View

Sobel B, SARNOFF S, Nachowiak D . Augmented and sustained plasma concentrations after intramuscular injections of molecular variants and deglycosylated forms of tissue-type plasminogen activators. Circulation. 1990; 81(4):1362-73. DOI: 10.1161/01.cir.81.4.1362. View

Tashiro K, Hagiya M, Nishizawa T, Seki T, Shimonishi M, Shimizu S . Deduced primary structure of rat hepatocyte growth factor and expression of the mRNA in rat tissues. Proc Natl Acad Sci U S A. 1990; 87(8):3200-4. PMC: 53863. DOI: 10.1073/pnas.87.8.3200. View

Madison E, Goldsmith E, Gerard R, Gething M, Sambrook J . Amino acid residues that affect interaction of tissue-type plasminogen activator with plasminogen activator inhibitor 1. Proc Natl Acad Sci U S A. 1990; 87(9):3530-3. PMC: 53935. DOI: 10.1073/pnas.87.9.3530. View

Higgins D, Bennett W . Tissue plasminogen activator: the biochemistry and pharmacology of variants produced by mutagenesis. Annu Rev Pharmacol Toxicol. 1990; 30:91-121. DOI: 10.1146/annurev.pa.30.040190.000515. View

Dihanich M, Monard D . cDNA sequence of rat prothrombin. Nucleic Acids Res. 1990; 18(14):4251. PMC: 331193. DOI: 10.1093/nar/18.14.4251. View

Wilhelm J, Lee S, Kalyan N, Cheng S, Wiener F, Pierzchala W . Alterations in the domain structure of tissue-type plasminogen activator change the nature of asparagine glycosylation. Biotechnology (N Y). 1990; 8(4):321-5. DOI: 10.1038/nbt0490-321. View

Wurm F . Integration, amplification and stability of plasmid sequences in CHO cell cultures. Biologicals. 1990; 18(3):159-64. DOI: 10.1016/1045-1056(90)90002-h. View

10.

Bennett W, Paoni N, Keyt B, Botstein D, Jones A, Presta L . High resolution analysis of functional determinants on human tissue-type plasminogen activator. J Biol Chem. 1991; 266(8):5191-201. View

11.

Collen D, Lijnen H, Vanlinthout I, Kieckens L, Nelles L, Stassen J . Thrombolytic and pharmacokinetic properties of human tissue-type plasminogen activator variants, obtained by deletion and/or duplication of structural/functional domains, in a hamster pulmonary embolism model. Thromb Haemost. 1991; 65(2):174-80. View

12.

Bovill E, Terrin M, Stump D, Berke A, Frederick M, Collen D . Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II Trial. Ann Intern Med. 1991; 115(4):256-65. DOI: 10.7326/0003-4819-115-4-256. View

13.

Lijnen H, Collen D . Strategies for the improvement of thrombolytic agents. Thromb Haemost. 1991; 66(1):88-110. View

14.

de Vos A, Ultsch M, Kelley R, Padmanabhan K, Tulinsky A, Westbrook M . Crystal structure of the kringle 2 domain of tissue plasminogen activator at 2.4-A resolution. Biochemistry. 1992; 31(1):270-9. DOI: 10.1021/bi00116a037. View

15.

Neuhaus K, von Essen R, Tebbe U, Vogt A, Roth M, Riess M . Improved thrombolysis in acute myocardial infarction with front-loaded administration of alteplase: results of the rt-PA-APSAC patency study (TAPS). J Am Coll Cardiol. 1992; 19(5):885-91. DOI: 10.1016/0735-1097(92)90265-o. View

16.

Bassel-Duby R, Jiang N, Bittick T, Madison E, McGookey D, Orth K . Tyrosine 67 in the epidermal growth factor-like domain of tissue-type plasminogen activator is important for clearance by a specific hepatic receptor. J Biol Chem. 1992; 267(14):9668-77. View

17.

van Loon B, Rijken D, Brommer E, van der Maas A . The amount of plasminogen, tissue-type plasminogen activator and plasminogen activator inhibitor type 1 in human thrombi and the relation to ex-vivo lysibility. Thromb Haemost. 1992; 67(1):101-5. View

18.

Otter M, Zockova P, Kuiper J, Van Berkel T, Barrett-Bergshoeff M, Rijken D . Isolation and characterization of the mannose receptor from human liver potentially involved in the plasma clearance of tissue-type plasminogen activator. Hepatology. 1992; 16(1):54-9. DOI: 10.1002/hep.1840160111. View

19.

Orth K, Madison E, Gething M, Sambrook J, Herz J . Complexes of tissue-type plasminogen activator and its serpin inhibitor plasminogen-activator inhibitor type 1 are internalized by means of the low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor. Proc Natl Acad Sci U S A. 1992; 89(16):7422-6. PMC: 49722. DOI: 10.1073/pnas.89.16.7422. View

20.

Paoni N, Refino C, Brady K, Pena L, Nguyen H, Kerr E . Involvement of residues 296-299 in the enzymatic activity of tissue-type plasminogen activator. Protein Eng. 1992; 5(3):259-66. DOI: 10.1093/protein/5.3.259. View